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From the Editor’s Desk
Haemostasis is a physiological process, which
keeps the blood clot-free inside vessels and
initiates clotting if a vessel is injured. Under
normal circumstances, a fine balance is
maintained preventing both thrombosis and
bleeding. Hence, disorders that interfere with
the normal functioning of any of the parameters
involved in clotting like endothelial lining,
platelets and clotting factors would lead to
bleeding. AKUH’s Clinical Laboratory offers
a wide panel of bleeding and thrombophilia
testing that can be effectively utilized in proper
evaluation of the patients with haemostatic
abnormalities. This issue is an attempt to
provide physicians with information on
haemostatic abnormalities that should help
in screening and diagnosing of the diseases.
The first part of the issue focuses on common
bleeding disorders. An appropriate work-up
of suspected bleeding disorder is presented.
Specialised testing is recommended in consultation
with a haematologist. It is also important that
patients who are diagnosed with bleeding disorders
should be managed optimally. In patients requiring
frequent blood transfusion, there is increased
Pro-coagulants

likelihood of transfusion-associated-viral infections
such as HIV, hepatitis B and C. Recently, Clinical
Laboratory introduced nucleic acid testing that has
enhanced safety of blood products by eliminating
window-period donations.
The latter part of this issue addresses
thrombophilia which is an inherited or acquired
predisposition of an individual for arterial or
venous thrombosis. AKUH Clinical Laboratory
offers a variety of tests that can assist in
diagnosis and management of not only inherited
but acquired thrombotic disorders. Protein C,
Protein S, factor V Leiden and antithrombin
tests are useful in inherited thrombophilia. Other
tests like anti-phospholipid antibodies (lupus
anticoagulants, anticardiolipin antibodies),
homocysteine, PNH and HIT antibodies are
reserved for acquired cases. In addition,
international normalised ration and anti-Xa
assay, which are used in monitoring of oral
anticoagulation and low molecular weight heparin
[LMWH] therapy respectively, are discussed.
Dr Bushra Moiz
Associate Editor, LABRAD
Anti-coagulants
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How to Investigate a Bleeding Disorder?
Dr Natasha Ali
Haematology

Bleeding is a very common symptom for which
patients approach doctors. At the same time,
bleeding disorders are a common reason for a
general practitioner to consult a haematologist.
Determining the cause of bleeding disorders is
challenging due to the variability of symptoms
from patient to patient and requires a stepwise
approach which traces each case from history to
laboratory investigations. Questions usually focus
on three main causes of bleeding: impaired vascular
integrity, thrombocytopenia or platelet dysfunction
and deficiency of clotting factors. The clinical
manifestations of any bleeding disorder depend on
the nature of defect and its severity.

Physical Examination
The underlying cause can be determined by carefully
examining the patients. Usually low platelets or platelet
dysfunction produce muco-cutaneous bleedings [Fig.
1] while clotting factor deficiency results in a cavity
bleed for example within joints, abdominal cavity,
muscle, etc. [Fig. 2].

History
Table 1. Questions for a Patient Suffering from a Bleeding
Disorder

Onset of bleeding – to distinguish between
hereditary and acquired bleeding disorders

Fig. 1. Petechiae (small pinpoint cutaneous bleeding due to platelet defect
or low platelets)

Type of bleeding – whether it is muco-cutaneous or
within a cavity
Severity of bleeding – patient is asked whether
the symptoms occur spontaneously or during
haemostatic challenge e.g. surgical procedures,
road traffic accidents, etc.
Frequency of bleeding.
Timing of bleeding episode – whether it occurs
immediately or is it delayed.
Are other members in the family affected?
Drug history which particularly includes use of
aspirin or NSAIDS
Nutritional history – deficiency of vitamin C
In case of an infant presenting with bleeding,
ask the parents regarding prolonged bleeding
during child’s circumcision or from his/her
umbilical stalk
4

Fig. 2. Hemarthrosis in a Hemophilia patient – bleeding within the knee
joint secondary to defective coagulation

Laboratory Investigations
Certain pre-requisites should be met before
collection of blood samples for lab tests. These are
listed in Table 2.
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Table 2. Pre-analytic Considerations for Coagulation Testing

Case 2

Patient should not have received recent transfusions
(blood, plasma products and platelets)

If an isolated APTT elevation is observed and the
patient has bleeding tendency then the APTT mixing
test can help to differentiate between factor VIII and
IX deficiency. Factor XI is also a remote possibility
[Fig. 4]. Von Willebrand Disease can lead to raised
APTT with elevated bleeding time. Presence of lupus
anticoagulants or factor XII deficiency can increase
APTT but patient will have no bleeding symptoms in
this case.

Patient should not be on medications like Aspirin,
NSAIDS or antibiotics (penicillin)
Patient should not be in stress (as it increases factor
VIII levels)
Patient should not be pregnant (as it increases Von
Willebrand factor antigen levels and factor VIII)
Screening tests: Any patient with a bleeding disorder
should be tested for basic coagulation profile. The
results of these will determine whether more specific
tests are required for diagnosis. These tests are listed
in Table 3.
Table 3 Screening Test for Investigating Bleeding Disorders

CBC including platelet count and peripheral film
review

PT-N
APTT- 
Platelet-N

Injury related
Mild to moderate Haemophilia A & B
Severe XI deficiency

Unprovoked

Mild bleeding
vWD

Severe bleeding
Severe Haemophilia
Type III vWD

Bleeding time
Prothrombin time [PT]
Activated partial thromboplastin time [APTT]
Urea clot lysis test for factor XIII
Specialised tests: Based upon the screening test results,
second line investigations are ordered for further work
up. Different approaches are used to diagnose a patient
depending on clinical details and screening tests. The four
possible common scenarios are described below:
Case 1
If only PT is prolonged with normal platelet count and
APTT, then factor VII deficiency should be suspected
[Fig. 3]. Factor VII assay will help in establishing
definitive diagnosis.
PT-
APTT-N
Platelet-N

Bleeding
Severe factor VII
deficiency

No bleeding
Mild factor VII
deficiency, Use of oral
anticoagulants

Fig. 3. Algorithm for Isolated Prolonged PT

Fig. 4. Algorithm for Isolated Prolonged APTT

Case 3
Combined elevation of PT and APTT raises the
possibility of deficiencies of factors in common
pathways such as I, II, V and X. Common causes are
vitamin K deficiency in neonates or infants and liver
disorders in adults. Anticoagulation therapy also leads
to raised PT and APTT [Fig. 5].

PT-
APTT-
Platelets-N

Bleeding
Deficiency of common
pathway factors. Combined
factor V&VIII deficiency
Vitamin K deficiency

No bleeding
Mild deficiency of common pathways factors

Fig. 5. Algorithm for Combined Elevation of PT and APTT

5
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Case 4

PT-
APTT-
Platelets-r

Profound disturbance of primary screening results
are indicative of global haemostatic abnormalities
such as advanced hepatic disorder or disseminated
intravascular coagulation (DIC) (Fig. 6).
In summary, while investigating a patient for suspected
bleeding disorder, a thorough clinical history and
physical examination is of paramount importance
since majority of the disorders can be diagnosed with
these two tools. Additionally, appropriate laboratory
testing and timely consultation with a haematologist
experienced in dealing with bleeding disorders are

Bleeding
DIC Liver disease
Lupus anticoagulants

No bleeding
Same causes

Fig. 6. Algorithm for Eelevation of all Primary Screening Investigations.

the key features of successful management of these
patients.

Nucleic Acid Testing at AKUH
Sana Chundrigar
Molecular Pathology

In recent years, despite improvements in serological
tests for HCV, HBV and HIV infections, instances
of viral transmission via transfusion still occur
because of donations that take place while a donor
is either in the pre-seroconversion window phase,
infected with immunovariant viruses, or a nonseroconverting chronic carrier.
What is Nucleic Acid Testing and how does it help?
Nucleic Acid Testing, (NAT) is a highly sensitive
molecular method of testing blood donations for
viral nucleic acid. It is used to detect low level of
viral genetic material present in the blood specimen
even before the body begins producing antibodies in
response to the virus.
Detection of HIV I and II
11 days

25 days

Detection of HCV
12 days
Detection of HBV
25 days

75 days
60 days

NAT testing
Ag & Ab Detection
Fig. 1. Window period of HIV, HCV and HBV

6

NAT significantly reduces the ‘window period,’
which is the time between donor exposure to the
virus and the appearance of antibodies [Fig 1]. By
reducing the window period it further diminishes
occurrence of disease transmission via transfusion.
The performance of the NAT assay is essentially
dependent on both its analytical and clinical
sensitivity and specificity. The analytical sensitivity
is generally determined by testing dilutions of
standardised materials such as WHO International
Standards and subsequent calculations of 95 per
cent Limit of Detection (LOD). A NAT can be
conveniently performed on a mini-pool which is a
pool of six test samples.
Countries that have introduced NAT have
encountered a decrease in residual risk of viral
transmissions. Although other safety measures such
as more stringent selection of blood donors have
contributed as well as a marked decrease is evident
between pre- and post-NAT implementation. The
residual risk for HCV transmission prior to NAT
was 0.64 cases per million in France and 3.94 per
million in Spain which decreased to 0.1 per million
and 2.33 per million respectively after NAT was
adopted. HIV NAT yield rates were estimated at
0.3 per million donations in France and Spain as
opposed to 0.59 and 2.48 respectively preceding
NAT incorporation. There is potential that next
generation NAT testing could completely eradicate
transfusion risk of HIV, HCV and HBV.
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NAT at AKUH
The quality of blood products at the AKUH has further
improved by the recent addition of NAT testing in the
blood donor screening programme. There is automated
pooling of blood donations, sample preparation,
amplification (real time polymerase chain reaction or
PCR) and detection. [Fig.2].
1. Lysis, stabilisation
and deproteination

2. Capture

3. Wash

Real time data collection allows monitoring of
the PCR process in each individual cycle instead
of end point measurement after completion of all
cycles [Fig.3].

4. Elute

Fig. 2. Steps in Nucleic Acid Extraction

Before authorising for general use the NAT test
was validated on more than 1000 blood donations.
So far up to 18,000 blood donations have been
screened by NAT assay and unsurprisingly it
has captured many window period positive
specimens.

Fig. 3. Principles of the Real Time PCR

Lab Diagnosis of von Willebrand Disease
Bushra Afaq and Dr Bushra Moiz
Haematology

Von Willebrand Disease (VWD) is an autosomally
inherited congenital bleeding disorder resulting
from deficiency or dysfunction of von Willebrand
factor (VWF). The predominant clinical problems
are muco-cutaneous bleeds. Therefore, patients
usually present with petechiae, oral and gum
bleeding, nose bleeding or epistaxis. Excessive
menstrual loss or menorrhagia is a common
bleeding problem in women of reproductive
age. Circumcision acts as a good haemostatic
challenge in case of males and therefore boys may
be diagnosed earlier than girls. VWD has three
clinical types based on von Willebrand Antigen
(VWAg) levels.
Laboratory assessment for Von Willebrand Disease
Following are the laboratory tests which should be
performed for the laboratory diagnosis of VWD.

Bleeding time: It is performed by IVY method. Its
reference range is between 1-6 minutes
APTT: A clotting assay having a reference range
between 25-35 seconds.
VWAg: A quantitative determination of von
Willebrand activity by turbidimetric method. Its
reference range is between 50-160 per cent.
F-VIII: A clotting assay having a reference range
between 50-150 per cent.
R-COF: A quantitative determination of F-VIII
Ristocetin Cofactor activity using aggregometry
technique. Its reference value is >40 per cent.
RIPA: Ristocetin platelet induced aggregometry.
Normal platelets show response to standard strength
of ristocetin but fail to respond to a lower dose.
7

VOL. 38, ISSUE 1

JULY 2012

Results of the above stated laboratory tests are summarized in the Table 1.
Table 1. Expected Laboratory Values in Subtypes of VWD
Normal

Type 1

Type
2A

Type
2B

Type
2M

Type
2N

Type 3

VWF:Ag

N

L or r

ror L

ror L

ror L

N or L

absent

ror L

VWF:RCo

N

L or r

r

r

r

N or L

absent

r

FVIII

N

N or r

N or r

N or r

N or r

r

1-9 IU/dL

N or L

RIPA

N

often N

r

often N

r

N

absent

often N

BT

N

N or 





N

N





Platelet
Count

N

N

N

N or r

N

N

N

r

r

Decreased activity in comparison to reference range



More than normal range

PLTVWD

N Normal
L

Subnormal activity

AKUH’s Clinical laboatory offers a variety of tests required for diagnosis and characterisation of VWD.

Scoring Systems in Diagnosis of Disseminated
Intravascular Coagulation
Dr Natasha Ali
Haematology

The liver is the most important organ involved
in the regulation of haemostasis. Most of the
clotting factors, their inhibitors and a number of
proteins responsible for fibrinolysis are produced
in the liver. Therefore, liver disease impacts both
primary and secondary haemostasis pathways
through a number of different mechanisms.
Abnormalities of the clotting cascade are the
predominant features of acute and chronic liver
disease. In some patients suffering from hepatic
disease, physicians are faced with the diagnostic
challenge of an underlying bleeding or thrombotic
diathesis due to overlap between various clinical
syndromes including Disseminated Intravascular
Coagulation (DIC).
8

According to the International Society of Thrombosis
and Haemostasis (ISTH), DIC is a syndrome
characterised by a systemic intravascular activation
of coagulation, with loss of localisation, arising from
different causes. It can originate from and cause
damage to the microvasculature, which if sufficiently
severe can produce organ dysfunction. ISTH also
proposed that the working definition of DIC can be
divided into two phases:
a)

Non-overt DIC: represents subtle haemostatic
dysfunction

b) Overt DIC: de-compensated phase of non-overt
DIC
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Events responsible for DIC in liver disease include
liver necrosis, impaired endotoxin clearance,
surgery, shock and ascites recirculation. DIC can
be recognised as a syndrome suggested by clinical
signs and laboratory tests. The characteristic
laboratory findings include: prolonged prothrombin
time (PT), activated partial thromboplastin time
(APTT), thrombin time (TT), increased levels
of fibrin related markers (fibrin degradation
products, D-Dimer), decreased platelet count,
fibrinogen level, plasma coagulation factors and
their inhibitors. More specialised and useful tests
include: prothrombin activation fragments and
thrombin-antithrombin complex (TAT).
In 2001, ISTH proposed two separate scoring
systems for overt and non-overt DIC. The overt
DIC score consists of a five steps diagnostic
algorithm, in which a specific score, reflecting the
severity of the abnormality found, is given to each
of the laboratory tests [Table 1]. A score
Table 1. ISTH Score System for Overt DIC
Screening Tests
PLATELET COUNT

Findings
>100,000/μL
50,000-100,000/ μL
<50,000/ μL
PROTHROMBIN
(PT upper limit of reference
TIME
range) >3 secs
(PT upper limit of reference range)
=3-5.9 secs
(PT upper limit of reference range)
≥6 secs
FIBRINOGEN
>100mg/dl
<100mg/dl
FIBRIN MONOMER No increase
Moderate increase
Severe increase

Points
0
1
2
0
1
2
0
1
0
2
3

of five or more is considered to be
compatible with DIC, whereas a score of
less than five may be indicative (but not
affirmative) for non-overt DIC. Similarly using
certain clinical and laboratory findings [Table
2] a score of five or greater is compatible with
Table 2. ISTH Score for non-Overt DIC
Parameter
Diagnosis

Findings
Not associated with DIC
Associated with DIC
Platelet count
>100,000/μL
<100,000/μL
Prolongation of PT
< 3 seconds
> 3 seconds
Soluble fibrin or FDP Normal
Increased
Antithrombin III
Normal
Low
Protein C
Normal
Low

Points
0
2
0
1
0
1
0
1
-1
1
-1
1

non-overt DIC and could diagnostically define
patients with a poor prognosis due to haemostatic
dysfunction, independent of developing overt
DIC.
Following steps are suggested for the diagnosis
of DIC:
Step 1: Determine if the patient has an
underlying condition associated with DIC. If no
underlying is present then do not proceed further.
Step 2: Order screening coagulation tests and
decide whether patient has overt or non-overt
DIC.

Plasma and Platelet Transfusions in Liver
Diseases
Dr Farrukh Ali Khan
Haematology

Liver disease impacts
secondary haemostatic
number of mechanisms.
associated coagulopathy
major contributor to
Both acute liver failure

both the primary and
pathways through a
Historically, liver disease
has been considered a
bleeding complications.
(ALF) and chronic liver

disease (CLD) result in reduced synthesis of
pro- and anticoagulant factors and are associated
with thrombocytopenia and platelet dysfunctions.
Additionally, cholestatic liver disease resulting from
obstruction in biliary tree is also associated with
coagulopathy.
9
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Routine correction of liver disease associated
coagulopathy is not required in non-haemorrhagic
patients.

monitor placement in ALF. Further research is
required to determine an optimal management
strategy.

Vitamin K deficiency is common in ALF and
cholestatic liver disease and replacement of
Vitamin K should be considered in these patients.
Additional therapy may be required during
episodes of variceal bleeding, surgery and prior to
invasive procedures. However, the role of plasma
and platelet infusion prior to invasive procedures
is not well-established. Paracenteses and central
venous access can be undertaken safely even in the
presence of coagulopathy and thrombocytopenia,
and bleeding post-liver biopsy is not predicted by
abnormal laboratory markers.

Recombinant Factor VIIa (rFVIIa) has been
investigated as an alternative agent for the
correction of PT in ALF and to reduce blood loss in
those with bleeding varices, prior to liver biopsy,
liver resection and during liver transplantation.
These studies have demonstrated that although
rFVIIa administration leads to normalisation of
the PT, there was no associated reduction in
bleeding. It is not approved for use in liver disease
and is associated with a significant increase in
arterial thromboembolic events when used outside
its approved indications.

The British Committee for Standards in
Haematology Blood Transfusion Taskforce (2004)
suggested that there is insufficient evidence
to support prophylactic transfusion of fresh
frozen plasma (FFP) in those with a prolonged
pro thrombin time (PT) prior to liver biopsy.
Furthermore, the response to FFP infusion in
patients with liver disease is highly variable, with
less than 15 per cent of patients achieving an
appropriate correction of PT following infusion
of FFP in one study. The use of FFP can result
in additional complications;
large
infusion
volumes can lead to volume overload, with
subsequent exacerbation of portal hypertension,
ascites and intracranial hypertension, in addition
to the risk of infection and transfusion related acute
lung injury.

Prothrombin
complex
concentrates
(PCC:
containing Vitamin K-dependent coagulation
factors) may have an advantage over FFP with
smaller volume for delivery of factor replacement
and rapid correction of haemostatic parameters.
However, caution is required in patients with liver
disease due to the risk of DIC and thromboembolic
complications. There are no randomised controlled
trials assessing the efficacy and reduction in
bleeding risk with PCC in patients with liver
disease.

In those with disseminated intra vascular
coagulation (DIC) and bleeding, FFP administration
may be useful. In this setting, in the presence of
persistent hypo brinogenaemia and continued
bleeding following FFP, cryoprecipitate or brinogen
concentrate may be used.
Platelet transfusion should be considered in
the presence of bleeding and a platelet count
of <10 x 109/l or prior to invasive procedures
in those with a platelet count of <50 x 109/l.
Increments may be poor following platelet
transfusion in those with hypersplenism, active
bleeding or coexistent infection. Given the lack
of evidence and efficacy in this area it may be
more appropriate to adopt an expectant
management strategy, whereby FFP is reserved
for those who develop bleeding complications.
However, this approach is considered too risky
for some procedures, such as intracranial pressure
10

Anti-fibrinolytic agents, including tranexamic
acid, aprotinin and e-aminocaproic acid, have
been used successfully to control bleeding during
liver transplantation and reduce transfusion
requirements in this setting. However, their routine
use has recently been challenged and their role in
liver disease outside the transplant setting has not
been established yet. The use of desmopressin
(1-deamino-8-d-arginine-vasopressin,
DDAVP)
has been investigated in liver disease but no
improvement in clinical outcome was seen in
those with variceal bleeding or those undergoing
transplantation.
There may be a future role for thrombopoietin
mimetics in the treatment of thrombocytopenia
associated with CLD. A phase 2 study of
Eltrombopag in patients with HCV-associated
cirrhosis demonstrated its efficacy in raising
platelet counts sufficiently to allow commencement
of antiviral therapy.
Further clinical trials are awaited; there may be
a further role for these agents in amelioration
of thrombocytopenia in patients with CLD prior
to procedural interventions.
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Ristocetin Cofactor Activity
Bushra Afaq
Haematology

Ristocetin Cofactor (RCo) measurement is essential
for the diagnosis of von Willebrand disease (VWD).
VWD is an autosomally-inherited congenital bleeding
disorder that is caused by deficiency or dysfunction
of von Willebrand factor (VWF), a plasma protein
that mediates the initial adhesion of platelets at
site of vascular injury and also binds and stabilises
blood clotting factor VIII (FVIII) in the circulation.
Therefore, defects in VWF can cause bleeding
by impairing platelet adhesion or by reducing the
concentration of FVIII.

tested in the presence of Ristocetin and reconstituted
platelets and an aggregation pattern is determined.
RCo Activity of test plasma is interpolated from the
standard curve [Fig. 1].

VWD is classified into three major categories:
1. Type 1: a quantitative deficiency of VW
factor (<30 per cent)
2. Type 2: a qualitative defect of VWF having
dysfunctional proteins. Type 2 has further
subtypes (2A, 2B, 2M, 2N) based on
laboratory tests.
3. Type 3: a severe deficiency of VWF (<3 per cent)
The RCo Assay is used in the quantitative
determination of RCo activity in citrated plasma.
It is particularly useful in detection of type 2A, 2B,
and 2M VWD, where the VWF: Ag may be normal
or near normal whereas the VWF: RCo is markedly
reduced.
RCo Activity in plasma may be determined by
the agglutination of a standardised suspension of
platelets in the presence of von Willebrand factor
using the antibiotic called Ristocetin. The RCo
Activity is the in-vitro activity of the von Willebrand
factor, which is responsible for the agglutination of
platelets in the presence of Ristocetin. Levels of
RCo activity are determined by the ability of the
test plasma and Ristocetin to induce aggregation in
a standardised platelet suspension.
Principle of the test method is reconstituted lyophilised
platelets are treated with Ristocetin in the presence
of varying dilutions of normal standardised human
plasma having known amounts of RCo Activity. A
standard curve is thus prepared. Patient plasma is then

Fig. 1. Standard Curve and Interpolation of Ristocetin Cofactor Activity for the Patient

Results of less than 40 per cent RCo (von
Willebrand Factor) are generally considered
abnormal and are indicative of von Willebrand
disease.
As a quality control of deficient von Willebrand
Reference Plasma is included in the test kit to function
as an abnormal Control. The RCo value of this Control
is less than 30 per cent.
The RCo assay is considered by many investigators
to be the single most important assay for VWD.
However, a complete diagnosis and determination
of the variant forms of this coagulopathy requires an
evaluation of family history and lab parameters such
as Von Willebrand antigen, Factor VIII activity and
bleeding time.
The test is available at Aga Khan University Hospital’s
clinical laboratory.
11
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All You Need to Know About Thrombophilia
Screening
Dr Bushra Moiz
Haematology

What is thrombophilia?

Selection of patient for heritable thrombophilia

Heritable thrombophilia is an increased tendency
towards venous thrombosis. Initially the terminology
was reserved for inherited disorders only but later
the term ‘thrombophilia’ was used loosely for both
inherited and acquired disorders with a predisposition
for either venous or arterial thrombosis.

The inherited thrombophilia screening in an unselected
patient population is not advisable. Since it is genetic,
testing with personal and family considerations
therefore patients should be carefully chosen. Not
every patient with thrombosis requires this testing.
Table 2 and 3 summarise the conditions in which
screening should not be performed. The information
provided is according to the guidelines published by
the British Committee of Standards in Haematology.

Assessment of thrombophilia
1. Clinical: Assessment of thrombophilia starts
with detailed clinical history and physical
examination. The patient should be assessed
for acquired risk factors, medication and comorbids.
2. Laboratory: The tests are listed in Table 1.
All the mentioned tests are offered by the
clinical laboratory at AKUH.

What are the appropriate timings of testing?
There is seldom any point in striving to obtain
samples for thrombophilia testing when the patient
presents with deep venous thrombosis (DVT)
or pulmonary embolism (PE). During an acute
thrombotic episode, patients usually have low
levels of protein C, protein S and antithrombin III

Table 1. Comprehensive Panel of Thrombophilia Testing

Test
Routine

Specialised

CBC, PT, APTT, Liver function tests
and Serum creatinine

To determine safety profile before initiation of
heparin and warfarin

Protein C, protein S, anti-thrombin III,
activated protein C resistance(APCR)

Required in investigation of heritable
thrombophilia

Anticardiolipin antibodies (IgM and
IgGO), lupus anticoagulants,
serum homocysteine levels

Required in acquired thrombophilia

PNH screening (CD55and 59)

Required for suspected PNH (intravascular
haemolysis and pancytopenia)

HIT

For suspected HIT (heparin induced
thrombocytopenia)
Needed for suspected TTP (micro-angiopathic
haemolytic anaemia, thrombocytopenia, renal
insufficiency and neurological deficit)

Ancillary

ADMATS-13 assay

JAK-2 V617F mutation

12

Purpose

For suspected myeloproliferative disorder (MPD)
with erythrocytosis/leucocytosis/thrombocytosis

JULY 2012
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Table 2. Conditions Recommended for Thrombophilia Screening

Venous thrombosis at an early age ( <40 years)
Venous thrombosis in a patient with thrombosis prone family ( >2 symptomatic family members)
Neonates and children with fulminating purpura (purpura fulminans) for protein C and S
Adults with skin necrosis following warfarin therapy for protein C and S
Case finding of asymptomatic relatives for high risk such as protein C and S deficiencies in thrombosis
prone families
Women requiring contraceptives or hormone replacement therapy with high risk thrombophilia in symptomatic relative
Pregnancy with previous travel related thrombosis
Asymptomatic pregnant woman with family history of thrombosis which was either unprovoked or provoked
by pregnancy, combined oral contraceptives (COC) exposure or traveling

Table 3. Conditions Which Should not be Tested for Heritable Thrombophilia

Unselected patients with first episode of thrombosis
First episode of cerebral venous thrombosis
Arterial thrombosis
Paediatric stroke
Hospital acquired venous thrombosis
Asymptomatic relatives of low risk thrombophilia (factor V Leiden, prothrombin gene mutation).
Retinal vein occlusion
First event of an intra-abdominal vein thrombosis
Pregnant women with previous unprovoked thrombosis
Pregnancy with previous trauma/surgery related thrombotic event
Pregnancy or COC related thrombosis
Unselected patients with upper limb thrombosis
Central Venous Catheters related thrombosis

13

VOL. 38, ISSUE 1

JULY 2012

as the two are consumed in an attempt to natural
thrombolysis. This results in false low levels of these
proteins. Testing should be delayed for at least one
month after discontinuation of oral anticoagulation.
Pregnancy and oestrogen reduce protein S levels
significantly and increase resistance to APC. If
possible, thrombophilia testing should be avoided
in inter-current illnesses, pregnancy and with oral
contraceptive usage.

How should I interpret the tests?

How should I collect blood samples?

Do I need repeating the tests?

The blood sample should be collected in standard
sodium citrate bottle/blue top vacutainer in a ratio
of 9:1 for lupus anticoagulant, protein C, S, APC,
and AT-III. EDTA blood sample is required for HIT,
PNH and JAK-2. Clotted blood sample is needed for
anticardiolipin antibodies and homocysteine.

Repeat testing for protein C, S and anti-thrombin III is
indicated and a low level should be confirmed on one
or more separate samples. Diagnosis of deficiency
should not be made on a single abnormal test.

Methodology assays used at AKUH clinical
laboratory

Initiation and intensity of anticoagulation following
diagnosis of acute venous thrombosis in a patient
should be the same with or without thrombophilia.
Testing of thrombophilia in selected patients with
strong family history of unprovoked thrombosis
may influence decision regarding duration of
anticoagulation.

The thrombophilia screening should be supervised
by experienced laboratory staff and the clinical
significance should be made in consultation with an
experience haematologist who is aware of relevant
factors that may affect test results in each case. The
factors affecting thrombophilia testing resulting in
spurious assessment is listed in Table 5.

Would the testing affect patient management?

At AKUH, functional assays are used for heritable
thrombophilia which have acceptable accuracy and
precision. Table 4 shows the various tests and their
methodologies used at AKUH.

Table 4. Tests and their Methodologies Used at AKUH Clinical Laboratories

Clinical utility
Protein C

Chromogenic assay

Protein S

Clotting based assay

Antithrombin III

Chromogenic assay

APCR
Lupus anticoagulant

Clotting based assay

Anticardiolipin antibodies

ELISA

Serum homocysteine

Immunogenic microparticulate
assay

PNH

PNH screening

Gel immunoassay

HIT

HIT screening

Gel immunoassay

TTP
MPD

ADAMTS-13
JAK-2 V 617 F

ELISA
PCR

Heritable thrombophilia

Acquired thrombophilia
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Table 5. Conditions Giving Rise to Misleading Results in Thrombophilia Screening

Acute thrombosis
Anticoagulants- heparin and warfarin
Direct thrombin inhibitors e.g. argatroban, lepirudin, bivalirudin
Liver disease
Pregnancy and COC

Significance of Antiphospholipid Antibodies
Dr Maria Riaz
Chemical Pathology

Membrane phospholipids participate in important
cellular functions including exchange of
metabolites across membrane, transferring
molecular signals and serving as a platform
for the assembly of protein-lipid complexes.
Natural autoantibodies to complexes of
negatively charged phospholipids and plasma
proteins are present in low concentrations (1-5
per cent) in healthy individuals. However, their
concentration is markedly increased in certain
diseases and therefore is used for diagnosis and
monitoring of the disease entity.
Antibodies to phospholipids are mainly of
three types which are closely related: lupus
anticoagulant antibodies (LAC), anti-cardiolipin
antibodies (ACA) and anti-β2 – glycoprotein
I antibodies (anti-B2GPI). Minor phospolipid
antibodies include prothrombin, annexin V,
phosphatidylserine and phosphatidylinositol.
The antiphospholipid antibody assays vary
in different patients with similar clinical
manifestation. Some patients are positive
in all antiphospholipid antibody assays while
others are only positive for one or two of these
assays.
ACA are autoantibodies against mitochondrial
phospholipid and were the first phospholipid
antibodies to be identified. It is less antigenic
compared to other APA. It may elevate in
conditions such as acute infection (32 per cent),

rheumatoid arthritis (4-25 per cent), drug induced
lupus (47 per cent) and elderly patients (52 per
cent). It either binds directly to phospholipids or
may require the presence of β 2-GP1.
LAC has higher thrombotic potential than ACA.
It is also thought to be more specific compared
to ACA. LAC has recently been thought to react
against prothrombin and results in prolonged
APTT; 85 per cent of APS patients have both
LAC and ACA.
β 2-GPI antibody is an apolipoprotein with
anticoagulant activity through the inhibition
of the conversion of prothrombin to thrombin,
regulation of protein S, and/or activation of
platelets. β 2-GPI is often included in ACA
assays to ensure the detection of both β 2-GPI
dependent as well as independent ACAs. β
2-GPI dependent ACA seems to be related
to autoimmune conditions whereas β 2-GPI
independent ACA tend to be associated more
with infections. β 2-GPI alone is found in 11per
cent of the APS patients.
The antiphospholipid antibody syndrome is also
known as the Hughes syndrome or the “sticky
blood syndrome.” It is a hypercoagulable
condition associated with both venous and
arterial thrombosis and pregnancy related
morbidities. APS may also show other
manifestations like thrombocytopenia and/or
15
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hemolytic anaemia, livido reticularis, cardiac
valve disease and nephropathy. Non-thrombotic
neurologic manifestations of APS include multiple
sclerosis like syndromes, chorea or migraine
headaches.
Antiphospholipid antibody syndrome is classified
as primary or secondary depending on the absence
or presence of other autoimmune disorders such as
SLE respectively.
The Sapporo criteria (2006) classifies the
antiphospholipid antibody syndrome on the basis
of one clinical and one laboratory manifestation as
shown in Table 1 while the indications for testing
are mentioned in Table 2.
Table 1. Sapporo Criteria for the Diagnosis of Antiphospholipid
Antibody Syndrome

Clinical
1. Arterial or vessel thrombosis – other than
superficial venous thrombosis in any tissue or
organ
2. One or more unexplained deaths of a
morphologically normal fetus (at/beyond the
10th week of gestation)
3. Three or more unexplained consecutive
spontaneous abortions (before the 10th week
of gestation) with no maternal anatomic/
hormonal abnormalities and no paternal/
maternal chromosomal causes
4. At least one premature birth of a
morphologically normal neonate (before the
34th week of gestation) due to eclampsia/
severe pre-eclampsia/placental insufficiency
Laboratory
1. Anti-cardiolipin IgG and/or IgM by ELISA on
two or more occasions, not less than 12 weeks
apart
2. Anti-β2 glycoprotein I IgG and/or IgM by
ELISA on two or more occasions, not less than
12 weeks apart
3. Lupus anticoagulant detected on two occasions
not less than 12 weeks apart according to the
guidelines of the International Society of
Thrombosis and Haemostasis
16
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Table 2. Indications for Testing Antiphospholipid Antibodies

Clinical criteria as mentioned in Table 1
Presence of a systemic rheumatic disease
especially SLE
Presence of an unexplained cutaneous circulatory
disturbance like, livido reticularis or pyoderma
gangrenosum
Unexplained thrombocytopenia or haemolytic
anaemia
Possible nonbacterial, thrombotic endocarditis
ACA are detected by enzyme immunoassays. LAC
have been detected using phospholipid responsive
clotting tests such as APTT, Kaolin clotting time (KCT)
and dilute Russell’s viper venom test (DRVVT). LAC
produces prolongation of phospholipid-dependent
clotting in vitro. Despite the “anticoagulant effect” in
vitro, these antibodies actually cause coagulation in
vivo, in the form of arterial and venous thrombosis.
At the AKUH Clinical Laboratory, Karachi, the
quantitative anticardiolipin IgG and IgM are measured
using the DIASTAT anti-cardiolipin kit by indirect
enzyme immunoassay method. The ACA panel
includes only IgG and IgM antibodies. The incidence
of IgA ACA is extremely low and their determination
is not helpful in the investigation of thrombosis or
other manifestations of the APLA syndrome.
For the detection of lupus anticoagulant, the AKUH
Clinical Laboratory uses the simplified DRVVT
method. In this method the LA1 (screening reagent) and
LA2 (confirmation reagent) are utilised and prolonged
clotting time is observed in positive samples.
Positive and strongly positive results for phospholipid
antibodies (≥or 60 GPL and/or MPL) are a diagnostic
criterion for antiphospholipid syndrome (APS).
Lesser levels of phospholipid antibodies and
antibodies of the IgA isotype may occur in patients
with clinical signs of APS but the results are not
considered diagnostic.
Surveys indicate that results of phospholipid antibody
tests can be highly variable and results obtained
with different commercial immunoassays may yield
substantially different results. ACA should be retested
after six to eight weeks to rule out transient antibodies
that are usually of no clinical significance.
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Homocysteine as a Risk Factor of Thrombosis
Rakhshanda Maher
Chemical Pathology

Elevated plasma homocysteine is associated with
increased incidences of cardiovascular mortality,
stroke, dementia and Alzheimer’s disease, bone
fracture and higher prevalence of chronic heart failure.
It was also shown that elevated plasma homocysteine
is a risk factor for preclampsia and neural tube
defects (NTD). Homocysteine has been implicated
in atherosclerotic and thrombotic vascular disease in
the general and in end-stage renal disease (ESRD)
population as well.
Homocysteine is a sulphur containing amino acid,
formed normally during metabolism of another
sulphur containing amino acid methionine. It is
metabolised by pathways, remethylation and transsulfuration of methionine (Fig 1). Approximately 50

An elevated plasma homocysteine level has been
found in patients with thrombotic disorders. In
actual thrombosis is a formation of blood clot inside
the blood vessel, obstructing the blood flow through
the circulating system. It is mainly classified into
venous and arterial thrombosis. The mechanism by
which homocysteine contributes to atherothrombosis
is complex and in vivo relevance is uncertain.
However in the Journal of Clinical Investigation2009, Jacoviner and his colleagues have reported a
unique mechanism in vivo by which homocysteine
may contribute to vascular disease. Accordingly,
there is impairment in the synthesis of endothelial
surface plasminogen which is the major fibrinolytic
agent. This leads to micro vascular dysfunction and
subsequent macro vascular occlusion in individuals
with hyperhomocystenemia.
Most studies so far have indicated normal
plasma homocystiene level to be in the range of
5 to 15 ul/L. However this does not imply that
there is no risk associated with homocystiene
levels between 10 to 15μl/L.

Fig. 1. Metabolism of Homocysteine

per cent of methionine is metabolised to cystathioinine
by cystathionine beta synthesase (CBS). This is
a one way reaction that permanently removes
homocysteine from the methionine cycle and initiates
the transsulfuration pathway for methyl group either
from N5 mehyltetrahydrofolate (in all tissues) or from
betaine (in liver and kidneys) to form methionine. The
former methylation step requires folate and vitamin
B12 as cofactors in trans-sulfuration pathways and
is effective when there is excess of methionine or
cysteine synthesis is required.

In 1990, the cut-off for homocysteine was
greater than 20μmole/L. This number
continued to go lower, and today, a level
somewhere around 12μmole/L is considered
as the recent cut-off. Homocysteine analyses
in The National Health and Nutrition
Examination Survey III (NHANES) results
shed some light into what constitutes ‘normal’
homocysteine levels in the US population.
A study conducted in 1999 by NHANES
investigators (published in Ann Intern Med
1999; 131:331) showed that homocysteine
levels continue to increase as a person ages, and men
have a higher mean concentration than women.
The AKUH Clinical Laboratory in Karachi, measures
the quantitative anticardiolipin IgG & IgM are
measured using the DIASTAT anti-cardiolipin kit by
indirect enzyme immunoassay method. The ACA panel
includes only IgG and IgM antibodies.The incidence
of IgA ACA is extremely low and their determination
is not helpful in the investigation of thrombosis or
other manifestations of the APLA syndrome.
17
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CD55 and CD59 for the Diagnosis of PNH
Fatima Azra Ausat
Haematology

Paroxysmal nocturnal hemoglobinuria (PNH)
is an acquired clonal hematopoietic stem cell
disorder induced by exposure to chemicals or
certain antibiotics and characterised by chronic
intravascular haemolysis, venous thrombosis,
defective haematopoiesis, frequent episodes of
infection and rarely, leukemic transformation.
Pathophysiology of PNH

Gel card tubes contain monoclonal antibodies
against CD55 and CD59; if cells express both
antigens the cells agglutinate by forming
antigen antibody complexes and bind the
mouse antibodies. After centrifugation through
the gel, cells carrying antibodies, confirming
the presence or MIRL or DAF, will show
a positive reaction, grade three-four in the
micro-tubes indicates the presence of a normal

Patients with PNH have a defective gene
called PIG-A, involved in the biosynthesis of
glycosylphosphatidylinositol
(GPI).Without
GPI, important regulatory proteins (e.g. CD55
or “DAF” and CD59 “MIRL”) cannot bind to
the surface and protect blood cells from attacks
of various proteins called complements. This
may result in a breakdown of erythrocytes and
release of haemoglobin which causes the urine
to turn dark during an episode (or “paroxysm”)
of haemolysis, though this is not found in all
cases.
There are certain diagnostic tests which are
used in the diagnosis of PNH including Ham’s
test, sucrose lysis test, and CD55 and CD59
analysis by flow cytometry and by using gel
card technique.
CD55 and CD59 determination by gel card
technique
Gel agglutination assay for PNH is a simple
method for screening red cells for deficiency
of GPI linked protein. For optimal results,
the determination should be performed using
a freshly drawn blood sample preferably into
EDTA, citrate or heparin, CPD-A anticoagulant.

18

Fig. 1. Gel card showing results for a normal person (three gel tubes on the
left) and from a patient suffering from PNH (three gel tubes on the right)

cell population. Cells deficient in MIRL or
DAF show a negative reaction as a compact
button at the bottom of the micro tube [Fig.1].
Double population of cells indicates a weak
positive PNH test. Whenever it is necessary to
know the amount of cells affected, a quantitative
test procedure such as flow cytometry should be
performed following a positive ID-PNH test.
PNH is only diagnosed where both MIRL and
DAF are shown to be deficient.
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Utility of ADAMTS-13 Assay
Dr Farheen Karim Mahar
Haematology

A Disintegrin and Metalloprotease with
Thrombospondin Type 1 Motif, 13 (ADAMTS13) is an enzyme which is released primarily from
the stellate cells of the liver but is also found in
platelets and endothelial cells. It is involved in
the regulation of the size of von Willebrand factor
(VWF) in plasma.
ADAMTS-13 maintains primary haemostasis by
proteolysing ultra-large von Willebrand Factor
(ULvWF). The latter is the hyperactive form of
vWF which is released from storage granules
(Weibel-Palade bodies) of endothelial cells
in response to inflammatory stimulation. The
ULvWF has more affinity for platelets favouring
platelet aggregation at sites of high shear stress
with subsequent formation of micro vascular
thrombi. The ULvWF relies upon ADAMTS-13 for
its cleavage and its conversion into a less active
form.
Deficiency of ADAMTS-13 may be congenital
(Upshaw-Schulman syndrome) or more often than
not acquired. An acquired deficiency is attributed to
the presence of auto-antibodies against ADAMTS13 which may either inhibit ADAMTS-13 function
or may cause rapid clearance of circulating
ADAMTS-13. Inherited or acquired deficiency of
ADAMTS-13 impairs ULvWF cleavage. Deficient
proteolysis of ULvWF results in disseminated
platelet-rich thrombi in the microcirculation
which in turn cause typical thrombotic microangiopathies resulting in end organ ischemia.

The laboratory assessment of ADAMTS-13 levels
is useful since severe deficiency of ADAMTS13 has been proposed as a specific laboratory
marker of thrombotic thrombocytopenic purpura
(TTP) or Upshaw-Schulman syndrome. It is
also seen in conditions like sepsis, disseminated
intravascular coagulation (DIC) and metastatic
malignancy. Mild to moderate deficiency is seen
in chronic inflammation, hepatic dysfunction and
pregnancy.
Given that severe secondary deficiency of
ADAMTS-13 might correlate with development of
widespread microvascular thrombi and end organ
injury, determination of ADAMTS-13 activity
at the time of hospital admission in patients with
severe conditions like sepsis and DIC will
help in understanding the extent of the disease.
It also raises the possibility of novel supportive
therapies for patients with sepsis and DIC such as
ADAMTS-13 supplementation and plasma therapy
because sepsis may have the same pathophysiology
of severe ADAMTS-13 deficiency for thrombotic
microangiopathies as idiopathic TTP.
The test is currently offered by clinical laboratories
of AKUH. It is based on the principle of enzyne
linked immuno sorvent assay (ELISA) technique.
Two to three millilitres of blood collected in citrate
anticoagulant is required for the test. The reference
range developed at AKUH for ADAMTS-13 is 175365 ng/dl. There is no difference in reference range
between males and females or adults and children.
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Critical International Normalised Ratio
Dr Shabneez Malik
Haematology

Oral anticoagulant therapy is commonly used in
the management of venous thrombosis such as
deep venous thrombosis of veins and pulmonary
embolism.
Previously, laboratories used to report prothrombin
time as a part of anticoagulation monitoring.
It was then found out that the prothrombin time
varied due to the difference in sensitivity of
various thromboplastins used in different clinical
laboratories. World Health Organization (WHO)
devised the term “International Normalised
Ratio” (INR) to reduce this inter-laboratory
variability.This term is self-explanatory. This is
a ratio of patient’s prothrombin time divided by
reference normal prothrombin time to the power
of a coefficient which is known as “international
sensitivity index.” This relates the sensitivity
of a given thromboplastin to the sensitivity of
WHO’s first international reference preparation of
thromboplastin (given an ISI of 1.0).
Monitoring of INR is critical in warfarinised
patients. Because of the narrow therapeutic
INR, patients on warfarin are stabilised within
a range of 2-3. Elevated INR can lead to
haemorrhagic complications on one hand while

sub-therapeutic INR can result in thrombosis.
Therefore accurate monitoring of INR is crucial
in preventing bleeding and thrombosis. The
goal of establishing critical INR is to alert
the physician to a potentially life threatening
bleeding or thrombosis requiring urgent
intervention. Critical INR value needs to be
established at local level as the line between
therapeutic and critical INR is thin.
The Seventh American College of Chest Physicians
Conference on Antithrombotic and Thrombolytic
Therapy recommended therapeutic intervention
in oral anticoagulant patients who have an INR
of 5.0 or greater. Therefore, critical INR in many
laboratories is 5.0. In 2000 College of American
Pathologist survey, 166 laboratories (27 per cent)
had chosen a critical INR of 5.0. Similarly an INR
below 1.5 should be considered critical for a patient
on oral anticoagulation as the patient is at risk for
thrombosis.
At AKUH, an INR of 5.0 or above is considered
critical. At this INR, the patient is contacted for
clinical details including medications. Patients are
advised to repeat INR and to consult their primary
physicians on emergency basis.

Anti-factor Xa Assay
Dr Natasha Ali
Haematology

Heparin is used widely for the prevention
and treatment of thromboembolic diseases,
during procedures of haemodialysis and
cardiopulmonary bypass surgeries. Two types
of heparin preparations widely in use today
are unfractionated heparin (UFH) and low
molecular weight heparin (LMWH). The
inconvenience and limited precision of monitoring of
(UFH) therapy has contributed to the increasing use
20

of LMWH preparations. The pharmacokinetic
properties of LMWH are different from (UFH)
and allows for easily monitored anticoagulant
effects of a given dose. Monitoring is,
however, recommended in clinical settings
like renal insufficiency, obesity, paediatric
patients and those on prophylactic anticoagulant
therapy in conditions like malignancy
or
anti-phospholipid
syndrome.
Anti-
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factor Xa assay is used to monitor LMWH
therapy.
Principle of anti-factor Xa is based on the fact
that both factor Xa and antithrombin III are
added in excess amounts to the test plasma
and the residual factor Xa activity is inversely
proportional to the heparin concentration. The
test is based on the assumption that the patient
has a normal concentration of antithrombin III.
The test is performed by adding a known
amount of factor Xa and antithrombin to the
plasma of the patient. If heparin or LMWH
is present in the patient plasma, it will bind
to antithrombin and inhibit factor Xa. The
amount of residual factor Xa is inversely
proportional to the amount of heparin in the
plasma. The amount of residual factor Xa is
detected by adding a chromogenic substrate
that resembles the natural substrate of factor
Xa. Factor Xa cleaves the chromogenic
substrate, releasing a coloured compound
that can be detected by a spectrophotometer.
Results
are
reported
as anticoagulant
concentration in anti-factor Xa units/ml,
such that high anti-factor Xa values indicate
high levels of anticoagulation. Deficiencies
of antithrombin in the patient do not affect
the assay, because excess antithrombin is
provided in the reaction.
S pecim en is c olle cted in sodium ci t rat e
b ottle ( blue top) about four hours aft er
subcutaneous injec tion of LMWH. B l o o d
sample s hould be de live re d to the la b o rat o ry
i mmediately or e lse false ly low valu es m ay
o ccur ( becau se platelets relea se p l at el et
factor 4 ( PF4) whic h ca n ne utra lise hep ari n
o r LM WH) . For the sa me rea son, p l as m a
mus t be s epa ra te d from c ells as s o o n
a s pos s ible, idea lly within one h o u r o f
specimen colle ction. P la sma c an be s t o red
for two hour s a t room tempe ra ture or can b e
fr ozen f or later testing.
Laboratory is specifically notified as to which
drug should be measured (heparin, LMWH).
Limitations of this test include cost issues
and less ready availability than the activated
partial thromboplastin time (APTT) for
heparin monitoring.

Table 1. Reference Ranges for Anti-Factor Xa

Heparin: 0.3-0.7 units/ml
LMWH: 0.4-1.1 units/ml for twice daily
subcutaneous dosing. For once daily
subcutaneous LMWH dosing, the therapeutic
range is less certain but is approximately 1-2
units/ml.
Target range for DVT prophylaxis (prevention):
There is no defined target range for prophylaxis
of deep vein thrombosis DVT because such
anticoagulation is not usually monitored.
When anti-Xa levels have been measured,
mean values are usually <0.45 units/ml.
Therapeutic range UFH: 0.3-0.7 U/L
Therapeutic range LMWH: 0.5-1.0 U/L
Prophylactic range UFH : 0.1-0.29 U/L
Prophylactic range LMWH: 0.20-0.49 U/L
Patients not on anticoagulants: 0 unit/ml.
Therapeutic range for anti-factor Xa for a
deep venous thrombosis (DVT) patient differs
according to the type of preparation used.:
Causes of Sub-Therapeutic Anti-factor Xa
Level
1. Specimen drawn at incorrect time (collection
times are four hours after injection of LMWH,
six hours after injection of danaparoid).
2. Specimen transportation time longer than two
hours.
3. Patient receiving prophylactic dose, therefore,
therapeutic range is not applicable and antiXa level is actually appropriate for dose.
Causes of Supra Therapeutic Anti-factor Xa
Level
1. Renal failure (with LMWH or danaparoid)
because of decreased renal clearance.
2. Heparin contamination, if specimen was
drawn from an IV heparinised line.

21

VOL. 38, ISSUE 1

JULY 2012

Detection of Heparin/Platelet Factor 4 Antibodies
Safia Naz
Haematology

Heparin-induced thrombocytopenia (HIT) is the
development of thrombocytopenia due to the
administration of Heparin. HIT predisposes to
thrombosis and when thrombosis is identified
the
condition
is
called
“Heparin-induced
thrombocytopenia and thrombosis (HITT).” Clinical
features associated with HIT syndrome primarily
include a decreased platelet count, risk of venous
or arterial thromboembolic complication and the
development of antibodies against a complex of
heparin and PF4. HIT is a life and limb threatening
condition. The diagnosis is made on clinical suspicion
requiring laboratory confirmation. The testing is
recommended in all patients whose platelet count
drop by 50 per cent of baseline within three to five
days of heparin administration. HIT is observed both
with unfractionated heparin and with low molecular
weight heparin though the risk is less with latter.
Several tests are available for detection of Heparin/
PF4 antibodies in the laboratory [Table 1]. Aga Khan
University Hospital, Clinical Laboratory uses IDPaGIA Heparin/PF4 Antibody Gel Test for detection
of these antibodies against this complex. The ID-

PaGIA Heparin/PF4 antibody test is a particle gel
immuno assay (PaGIA). High density synthetic
polymer particles are coated with heparin/platelet
factor 4 complex (HPF4). When these particles are
mixed with patient serum-specific antibodies of any
immunoglobulin class, they react with the HPF4A on
the bead surface, causing agglutination. When the
reaction mixture is centrifuged through a gel filtration
matrix, agglutinated particles are trapped on top of
the gel or distributed within the gel (positive reaction)
while free or non- agglutinated particles form a pellet
at the bottom of the micro tube (negative reaction).
Due to the strong red colour of these particles, the
result can be read visually with ease [Fig.1].

Fig. 1. Heparin/HP4 Gel Card showing Negative results for Patient One
and Two and Positive results for Patient Three and Four.

Table 1. Recommendation for laboratory Testing for Heparin Induced Thrombocytopenia Antibodies

Test

Methodology

Particle gel immunoassay
ID-Heparin/PF4 antibody
test (ID-H/PF4)

Patient serum and PF4 heparin-coated micro-beads are added to the incubation
chamber of the micro-column card and after five minutes, the card is
centrifuged. A strong positive result indicated by the agglutinated micro-beads
remaining top of the column.

Enzyme linked
immunosorbent assay
test (ELISA)

It detects all circulating antibodies that bind Heparin PF4 complexes and may
also falsely identify antibodies that do not cause HIT. Therefore, ELISA is more
sensitive but less specific requiring further testing.

Platelet aggregation test

Citrated platelet rich-plasma is used as an initial test for HIT, a positive result
generally supports the diagnosis of HIT and further testing is not required.
However negative test does not exclude HIT in a patient with a moderate or
high pre-test probability for HIT. In this situation washed platelets activation
assay should be performed.

Serotonin release
assay/washed platelets
activation assays

SRA is considered to be gold standard and is specific for the HIT antibodies.
The platelets are washed and mixed with serum and heparin. The sample is then
tested for the release of serotonin, a marker of platelet activation. If serotonin
release assay shows high serotonin release, the diagnosis of HIT is confirmed.
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The 4th Biennial Course in Chemical
Pathology
Dr Aysha Habib Khan
Chemical Pathology

Participants of the course at Armed Force Institute of Pathology

The 4th Biennial Course in Chemical Pathology
and Endocrinology was organised by Pakistan
Society of Chemical Pathologist (PSCP) at Armed
Forces Institute of Pathology (AFIP), Rawalpindi
on March 16 and 17, 2012.
The inaugural session was attended by pathologists
and their trainees from all over Pakistan. Dr
Farooq Ghani, Section Head Chemical Pathology
and Director Outreach of Clinical Laboratory, Dr
Imran Siddiqui, President PSCP, Drs Aysha Habib
Khan and Shireen Mansoor, members Executive
Council PSCP from Aga Khan University attended
the meeting.
In his welcome address at the inaugural session,
Commandant AFIP, Major General Farooq Ahmed
Khan, patron PSCP, updated the audience with the
recent advances and trends in the field of Chemical
Pathology. Chief Guest Lt General Azhar Rasheed
(Director General Medical Services, Pakistan
Army) appreciated the efforts of PSCP in educating
and treating patients.
The course comprised four teaching sessions
followed by a workshop on ethical practices in the
profession.
The sother peakers included Dr Shahzad Ahmed,
Clinical Endocrinologist (USA), Dr Jawaid Malick,
Rheumatologist, Fauji Foundation Hospital,
Brigadier Tahir Aziz, Immunologist from AFIP and
Lt Col Shakil Mirza, Hepatologist, Army Medical

Services. The presentations covered clinical
areas like diabetes, thyroid, osteoporosis, vitamin
D deficiency, role of autoantibodies, insulin
resistance in liver disease, placenta and foetal wellbeing, cystatin C as a marker of renal function,
biochemical investigations in liver diseases and a
view of novel cardiac biomarkers in heart failure.
A wide range of topics related to laboratory science
were also covered including metabolomic vs
clinical chemistry, improving efficiency in clinical
lab, the impact of STAT laboratory services in the
management of patients, selection of a clinical
chemistry instrument and a contrast approach
and lines of investigation including genomics and
metabolomics.
The post course workshop was well attended
by postgraduate trainees. It covered instrument
handling, scenarios related to lab management and
data interpretations.
The Executive Council and general body meeting
was held on March 16. The committee discussed the
IFCC scholarship award for enhancing the skills of
trainees under 40 years of age and increasing their
membership. The Committee decided to hold the
5th biennial conference of the society in February
2013 in Karachi.
The Executive Council thanked Brigadier Dilshad,
organising secretary of the biennial course for his
efforts in arranging the course.
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